West Pharmaceutical Services (NYSE:WST) Updates FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.000-6.200 for the period, compared to the consensus earnings per share estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

Analysts Set New Price Targets

WST has been the subject of a number of recent research reports. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their target price for the stock from $350.00 to $390.00 in a research report on Thursday, December 12th. StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Tuesday. Wolfe Research started coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Citigroup began coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target for the company. Finally, Bank of America increased their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and a consensus target price of $403.75.

West Pharmaceutical Services Stock Performance

West Pharmaceutical Services stock opened at $323.06 on Thursday. West Pharmaceutical Services has a fifty-two week low of $265.00 and a fifty-two week high of $408.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.23 and a current ratio of 3.00. The stock has a market cap of $23.40 billion, a P/E ratio of 47.93, a price-to-earnings-growth ratio of 19.31 and a beta of 1.01. The firm’s fifty day moving average price is $332.39 and its 200-day moving average price is $315.13.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. On average, equities research analysts expect that West Pharmaceutical Services will post 6.67 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th were paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.26%. The ex-dividend date was Friday, February 7th. West Pharmaceutical Services’s dividend payout ratio is currently 12.46%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.